If you are currently taking Gilenya®, and would like to join our panel of "Diarists" please contact the MSRC Webmaster at [email protected] Gilenya® (fingolimod) is the first in a new class of disease-modifying treatments called sphingosine 1-phosphate receptor (S1P-R) modulators and has a novel mode of action different from all currently marketed MS therapies. Gilenya® Diarists
© Multiple Sclerosis Resource Centre
|
Did you find this information useful? Would you like to comment on this page? Let us know what you think! We welcome all comments and feedback on any aspect of our website - please click here to contact us. |